

### PERSONAL INFORMATION **Antonio Blazquez**

#### WORK EXPERIENCE

---

- September 1996-June 2000 **Researcher**  
School of Pharmacy. Universidad de Salamanca (Spain)  
Pharmacoepidemiology research
- March 2001-July 2004 **Clinical Trial Manager**  
LICONSA (Spain)  
Clinical trial coordination.  
Regulatory Affairs.
- May 2005-April 2016 **Head of Unit**  
AEMPS (Spain)  
Clinical Assesor.  
Advisory functions.
- April 2016- Present **Deputy head of Department of Medicines for human use**  
AEMPS (Spain)
- September 2022- Present **Head of Department of Medicines for human use**  
AEMPS (Spain)

#### EDUCATION AND TRAINING

---

- 1991- 1996 **Pharmaceutical degree**  
Universidad de Salamanca (Spain)
- 1996- 2000 **Ph.D. in Pharmacy**  
Universidad de Salamanca (Spain)  
Pharmacoepidemiology
- 2011- 2012 **Máster en Evaluación Sanitaria y Acceso al Mercado**  
Universidad Carlos III de Madrid (Spain)  
Pharmacoeconomy  
Market Access

#### ADDITIONAL INFORMATION

---

- Expertise** More than 20 years of regulatory experience.  
Experience over the past 5 years in Spanish regulatory authority. Experience in the following Centralised procedures:  
Revolade.  
Irbesartan hydrochloride  
Emselex  
Experience in DC/MRP and national procedures.  
Scientific Advice.
- Publications** Blazquez Perez A, Mateos Campos R.The use of antitubercular drugs  
Blazquez Perez A, Valero Juan LF, Mateos Campos R, Saenz Gonzalez MC. Evolucion de la mortalidad por tuberculosis en Castilla y Leon 1987-1995. Centro de Salud 1999; 6: 386-390.

Blazquez Perez A, Valero Juan LF, Mateos Campos R, Saenz Gonzalez MC. Tuberculosis mortality in the elderly. Rev Clin Esp. 1999 Dec;199(12):862.

Blazquez Perez A, Mateos Campos R. Use of antituberculosis drugs in Spain 1996. Pharmacoepidemiology and Drug Safety. Volume: 8, Issue: 7, Date: December 1999, Pages: 523-528.

Alvarez Garcia MD, Blazquez Perez A, Mateos Campos R. Inappropriate antidiuretic hormone secretion syndrome associated with the use of selective serotonin reuptake inhibitors. Rev Clin Esp. 2000 Feb;2000(2):110-1.

Martinez MC, Blazquez A, Mateos R. Conocimiento de la tarjeta amarilla de farmacovigilancia por profesionales sanitarios. Atencion farmaceutica, 2000, vol 1:611.

R Rodriguez, R Briso Montiano, M Lopez, J Garcia, A Blazquez y R Mateos. Analisis epidemiologico de las consultas de urgencia en atencion primaria. SEMERGEN 2001; 27: 561 565.

Garcia-Arieta A, Blazquez-Perez A, de la Barrera PP, Pozo-Hernandez C, Vargas-Castrillon E. Regarding generic antiepileptic drugs. Rev Neurol. 2006 Oct 1-15;43(7):446-8; author reply 448.

N. Laguna-Goya, A. Blazquez-Perez, C. Pozo-Hernandez. Legislacion sobre autorizacion de genericos. Farm Hosp 2006, 30; 379-384.

Coautor del libro: Curso basico de derecho farmaceutico/ Edicion 2008. Editado por la Asociacion Espanola de Derecho Farmaceutico (ASEDEF) y Bayer Schering Pharma.

Gomez-Outes A, Suarez-Gea ML, Blazquez-Perez A, Pozo-Hernandez C, Vargas-Castrillon E. Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet. 2009 Aug 29;374(9691):682; author reply 683.

Gomez-Outes A, Suarez-Gea ML, Blazquez-Perez A, Pozo-Hernandez C, Vargas-Castrillon E. Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?. J Thromb Haemost. 2009.

Coautor de Recomendaciones sobre Portadoras en Hemofilia. COMISION CIENTIFICA DE LA REAL FUNDACION VICTORIA EUGENIA. Rodriguez-Martorell FJ et al. ISBN: 978-84-692-9583-0.

Coautor de Recomendaciones sobre Inmunotolerancia en Hemofilia. COMISION CIENTIFICA DE LA REAL FUNDACION VICTORIA EUGENIA. Villar A et al. ISBN: 978-84-693-1566-8.

Coautor de Recomendaciones sobre Rehabilitacion en Hemofilia y otras Coagulopatias Congenitas. COMISION CIENTIFICA DE LA REAL FUNDACION VICTORIA EUGENIA. Lopez Cabarcos C. et al. ISBN: 978-84-692-9917.

Coautor de Controversias actuales en la evaluacion de la investigacion biosanitaria. Guias operativas para CEIC/CEI-III. Coordinadora Ines Galende Dominguez. ISBN: 978-84-693-6799-5.

Garcia-Arieta A, Blazquez-Perez A. Interchangeability among therapeutics equivalents of lamotrigine. Rev Neurol. 2011 Mar 1;52(5):319-320.

Garcia-Arieta A, Blazquez A. Regulatory Considerations for Generic or Biosimilar Low Molecular Weight Heparins Curr Drug Discov Technol. 2011 Aug 15.

Garcia-Arieta A, Morales-Alcelay S, Herranz M, de la Torre-Alvarado JM, Blazquez-Perez A, Suarez-Gea ML, Alvarez C. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products. Int J Pharm. 2012 Feb 28;423(2):321-5.

Blazquez-Perez A, Garcia-Lopez L, Piqueras-Picon A. Funciones y actividad de la Oficina de Apoyo a la Investigacion Clinica Independiente de la Agencia Espanola de Medicamentos y Productos Sanitarios. Investigacion Clinica y Bioetica nº75. 2012.

Herranz M, Morales-Alcelay S, Corredera-Hernandez MT, de la Torre-Alvarado JM, Blazquez-Perez A, Suarez-Gea ML, Alvarez C, Garcia-Arieta A. Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison. Eur J Clin Pharmacol. 2013 May;69(5):1157-62.

Blazquez-Perez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics. 2013 Oct;31(10):919-31.

Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. San Miguel R, Gimeno-Ballester V, Blazquez A, Mar J. Gut. 2014 Oct 13.

Projects OPENMEDICINE

Memberships

Other Relevant Information